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http://www.biomedcentral.com/1471-2369/14/173RESEARCH ARTICLE Open AccessImpaired renal function impacts negatively
on vascular stiffness in patients with
coronary artery disease
Sabrina H Rossi1, Emily P McQuarrie1, William H Miller1, Ruth M Mackenzie1, Jane A Dymott1, María U Moreno1,2,
Chiara Taurino1, Ashley M Miller1, Ulf Neisius1, Geoffrey A Berg3, Zivile Valuckiene3, Jonathan A Hannay4,
Anna F Dominiczak1 and Christian Delles1*Abstract
Background: Chronic kidney disease (CKD) and coronary artery disease (CAD) are independently associated with
increased vascular stiffness. We examined whether renal function contributes to vascular stiffness independently
of CAD status.
Methods: We studied 160 patients with CAD and 169 subjects without CAD. The 4-variable MDRD formula was
used to estimate glomerular filtration rate (eGFR); impaired renal function was defined as eGFR <60 mL/min.
Carotid-femoral pulse wave velocity (PWV) was measured with the SphygmoCor® device. Circulating biomarkers
were assessed in plasma using xMAP® multiplexing technology.
Results: Patients with CAD and impaired renal function had greater PWV compared to those with CAD and normal
renal function (10.2 [9.1;11.2] vs 7.3 [6.9;7.7] m/s; P < 0.001). In all patients, PWV was a function of eGFR (β = −0.293;
P < 0.001) even after adjustment for age, sex, systolic blood pressure, body mass index and presence or absence of
CAD. Patients with CAD and impaired renal function had higher levels of adhesion and inflammatory molecules
including E-selectin and osteopontin (all P < 0.05) compared to those with CAD alone, but had similar levels of
markers of oxidative stress.
Conclusions: Renal function is a determinant of vascular stiffness even in patients with severe atherosclerotic
disease. This was paralleled by differences in markers of cell adhesion and inflammation. Increased vascular stiffness
may therefore be linked to inflammatory remodeling of the vasculature in people with impaired renal function,
irrespective of concomitant atherosclerotic disease.
Keywords: Coronary artery disease, Chronic kidney disease, Vascular stiffnessBackground
In patients with chronic kidney disease (CKD) cardiovas-
cular risk is at least in part mediated by vascular stiffen-
ing. Vascular stiffness increases with progression of CKD
[1] and is associated with cardiovascular mortality not
only in patients with end stage renal disease (ESRD) [2]
but also across all stages of CKD [3]. Vascular stiffness
has also been found to be a predictor of decline in renal
function in patients with CKD [4]. In patients with* Correspondence: Christian.Delles@glasgow.ac.uk
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reproduction in any medium, provided the orcoronary artery disease (CAD) and normal renal func-
tion aortic stiffness is an independent predictor of major
cardiac events [5]. Few studies, however, have examined
the contribution of renal impairment to vascular stiff-
ness in patients with established atherosclerotic disease.
Covic et al. [6] demonstrated that aortic pulse wave vel-
ocity predicts the extent and severity of coronary artery
disease in patients with CKD. We have previously dem-
onstrated using cardiac magnetic resonance imaging
(MRI) that aortic compliance is equally impaired in pa-
tients with CAD and in patients with ESRD [7]. More
recently, Ilyas et al. [8] demonstrated in patients with
various degrees of CAD that mild renal impairment is
associated with increased arterial stiffness.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the development of vascular damage in atherosclerosis [9].
The increased vascular stiffness in patients with renal im-
pairment, however, has also been attributed to arterial calci-
fication, inflammation and oxidative stress [10,11]. It is
unclear if renal impairment leads to acceleration of these
mechanisms in patients with atherosclerotic disease. We
therefore assessed carotid-femoral pulse wave velocity
(PWV) as a direct marker of vascular stiffness in patients
with and without CAD and studied whether mild to mod-
erate renal impairment further increases arterial stiffness
and if differences in PWV are paralleled by differences in
markers of inflammation, cell adhesion and oxidative stress.Methods
Participants
We included 160 patients with severe triple vessel CAD
who underwent elective coronary artery bypass graft sur-
gery at the Western Infirmary Glasgow between 2004
and 2008 [7,12-14]. Thirty nine patients with CKD
stages 2 to 4 who attend renal clinics at the Western In-
firmary Glasgow [15] and 130 healthy control subjects
who were recruited from a local sports centre, from a
surgical ward in Gartnavel General Hospital Glasgow or
were Glasgow University employees, also participated in
this study. Hence, a total of 329 subjects, 160 with CAD
and 169 without CAD, were studied (Table 1). As a re-
sult of rigorous quality checks not all of the parameters
below are available in all study participants.Table 1 Characteristics of the study cohort
CAD
n = 160
eGFR ≥60 mL/min eGFR
n = 105
Age (years) 62.2 [60.3;64.1] 69
Sex (% male) 90
Body mass index (kg/m2) 28.9 [27.9;29.9] 29
Active smoking (%) 18
Diabetes (%) 21
Systolic blood pressure (mmHg) 138 [134;143] 1
Diastolic blood pressure (mmHg) 77 [75;79]
Total cholesterol (mmol/L) 4.0 [3.8;4.2] 3
LDL cholesterol (mmol/L) 2.0 [1.9;2.2] 1
HDL cholesterol (mmol/L) 1.1 [1.0;1.2] 1
Serum calcium (mmol/L) 2.29 [2.27;2.31] 2.3
Serum phosphate (mmol/L) 1.10 [1.03;1.16] 1.1
eGFR (mL/min) 76 [73;78]
CAD coronary artery disease, eGFR estimated glomerular filtration rate, LDL low den
[95% confidence interval] or percentages as appropriate.Demographic data were collected and a blood sample
was taken to assess lipid profile, CRP, serum creatinine,
calcium and phosphate using standard biochemical
methods [7]. A lithium-heparinate sample was kept on ice
for a maximum of 1 hour prior to centrifugation. Plasma
was stored for biomarker analysis at −80°C. eGFR was de-
termined using the 4-variable MDRD formula, calibrated
to isotope dilution mass spectrometry reference. Impaired
renal function was defined as eGFR <60 mL/min.
The study adheres to the principles of the Declaration
of Helsinki and was approved by the West of Scotland
Research Ethics Committee (Reference Number 06/
S0703/110). All participants gave written informed consent.Pulse wave velocity and analysis
Carotid-femoral PWV was assessed using the SphygmoCor®
device (AtCor Medical Ltd., Sydney, Australia) as previously
described [16]. A measuring tape was used to assess the
distance between the carotid and femoral artery recording
sites. PWV was calculated automatically by dividing this
distance by the time interval between the rapid upstroke in
the pulse wave at the carotid and femoral arteries using the
peak of the R-wave on electrocardiography as a reference
point.Circulating markers of oxidative stress
Oxidised (GSSG) and reduced glutathione levels (GSH)
were determined in whole blood using a photometric
method (OXIS International Inc., Foster City, California,No CAD
n = 169
<60 mL/min eGFR ≥60 mL/min eGFR <60 mL/min
n = 55 n = 119 n = 50
.4 [67.5;71.4] 57.0 [54.8;59.0] 60.2 [56.6;63.8]
49 55 22
.7 [28.5;30.9] 26.0 [25.4;26.7] 28.9 [27.1;30.7]
10 10 14
35 0 13
46 [139;154] 136 [133;139] 143 [138;149]
78 [74;82] 80 [78;81] 80 [77;84]
.8 [3.5;4.0] 5.6 [5.4;5.9] 5.0 [4.2;5.8]
.8 [.16;2.0] 3.4 [3.2;3.6] 2.8 [2.2;3.4]
.2 [1.1;1.3] 1.5 [1.4;1.6] 1.5 [1.2;1.9]
7 [2.30;2.44] 2.35 [2.29;2.41]; 2.39 [2.35;2.42]
6 [1.05;1.27] 1.06 [0.88;1.24] 1.19 [1.11;1.27]
47 [43;50] 82 [80;85] 32 [28;36]
sity lipoprotein, HDL high density lipoprotein. Data are given as mean
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lipoprotein (LDL) cholesterol (oxLDL) was determined
using a competitive enzyme-linked immunosorbent
assay (Mercodia AB, Uppsala, Sweden).
Circulating biomarkers of inflammation and cell adhesion
Circulating biomarkers were assessed in plasma using
three WideScreen multiplex assays (Merck, Nottingham,
UK) on a Bio-Plex 100 xMAP platform (Bio-Rad, Hemel
Hempstead, UK). WideScreen Human CVD Panel 2
allowed multiplex analysis of interleukin-6 (IL-6),
macrophage inflammatory protein-1 alpha (MIP-1α),
interleukin-8 (IL-8), macrophage inflammatory protein-1
beta (MIP-1β), monocyte chemoattractant protein 1
(MCP-1) and tumour necrosis factor alpha (TNF-α).
WideScreen Human CVD Panel 3 was used to deter-
mine levels of E-selectin, P-selectin, intercellular adhe-
sion molecule-1 (ICAM-1), Leptin, Osteopontin and
soluble receptor of advanced glycation end-products
(sRAGE). WideScreen Human CVD Panel 6 allowed de-
termination of levels of Adiponectin, extracellular newly
identified receptor for advanced glycation end-products
binding protein (ENRAGE), plasminogen activator
inhibitor-1 (PAI-1), Cystatin C and vascular cell adhe-
sion molecule-1 (VCAM-1). Plasma samples were re-
moved from −80°C storage, carefully thawed on ice, and
prepared (diluted as required) according to the manufac-
turer’s instructions. Analyte levels were recorded from
100 microbeads per area of interest per sample, and each
sample was analysed in duplicate using the Bio-Plex sys-
tem, as per the manufacturer’s protocols. Data was
processed and analysed using xPonent® Software (version
3.1.871; Merck, Nottingham, UK). Coefficients of vari-
ation were consistent with the manufacturer’s published
data. Here we only report on biomarkers that passed the
quality checks and were detected in plasma of our
patients and control subjects; data for Cystatin C,7.5
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Figure 1 Renal function and pulse wave velocity in the whole study c
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* P < 0.05, ** P < 0.01; *** P < 0.001. B Scatterplot of pulse wave velocity vsinterleukin-6 and MIP-1a did not pass the quality con-
trol or were out of the range of the standard curve.
Mononuclear and whole cell superoxide production
Mononuclear cells were extracted from whole blood as
previously described and diluted to 5×106 cells/mL [18].
Superoxide production was measured in triplicate by elec-
tron paramagnetic resonance (EPR) spectroscopy (Bruker
BioSpin e-scan R, Bruker Corporation, Rheinstetten,
Germany) using the spin probe 1-Hydroxy-3-carboxy-
2,2,5,5-tetramethylpyrrolidine (CPH; Noxygen, Elzach,
Germany) [19]. Maximum superoxide production was
assessed after stimulation with phorbol 12-myristate 13-
acetate (PMA, 3.2 μM; Sigma-Aldrich, Dorset, UK) and
fold changes compared to basal production have been cal-
culated. For assessment of whole blood superoxide gener-
ation blood was collected in lithium heparinate containing
tubes, kept on ice and processed within half an hour. EPR
measurements were performed after adding the spin probe
CPH to a final concentration of 500 μmol/L [12]. Instru-
ment settings were: microwave power, 22 mW; centre
field, 3375 G; modulation amplitude, 2.27 G; sweep time,
5.24 s; sweep width, 60 G; 10 scans. Superoxide levels were
recorded once a minute for 10 min and the rate of super-
oxide anion production was calculated as counts per mi-
nute. For mononuclear cells this has been standardised to
a rate per 106 cells per minute whereas for whole blood
arbitrary units (AU) are presented.
Statistical analysis
Statistical analysis was conducted using SPSS statistical
package. Data are presented as mean [95% confidence
interval] or median [interquartile range] as appropriate.
Two sample Student’s t-test or Mann–Whitney U-test
were used to compare data between groups of patients.
Correlation was assessed by calculating Pearson’s (r) and
Spearman’s (ρ) correlation coefficients as appropriate.B
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eGFR calculated by the MDRD formula.
Table 2 Markers of oxidative stress
CAD No CAD P-value
n = 100 n = 93 CAD vs no CAD
eGFR ≥60 mL/min eGFR <60 mL/min P-value eGFR ≥60 mL/min
n = 67 n = 33
GSH (μmol/L) 992 [227] 894 [399] 0.067 1067 [270] 0.001
GSSG (μmol/L) 29.0 [63.5] 25.6 [71.1] 0.904 1.94 [24.5] <0.001
GSH/GSSG ratio 32.9 [569] 32.6 [513] 0.636 177 [709] 0.001
OxLDL (AU) 59.5 [35.6] 50.2 [33.6] 0.111 54.8 [24.5] 0.847
OxLDL/LDL ratio (AU/mmol/L) 28.5 [16.9] 28.4 [10.9] 0.612 17.6 [5.7] <0.001
Whole blood superoxide release (nmol/min/106 celles) 1.6 [2.2] 1.3 [1.0] 0.143 1.2 [0.6] 0.012
Basal mononuclear cell superoxide release
(nmol/min/106 cells)
2.5 [2.0] 2.2 [1.8] 0.504 1.8 [1.0] 0.005
Maximum (PMA) mononuclear cell superoxide release
(nmol/min/106 cells)
28.1 [21.2] 30.5 [23.4] 1.000 14.7 [9.7] <0.001
Fold change in mononuclear cell superoxide release 12.9 [7.1] 15.4 [9.2] 0.391 8.5 [5.4] <0.001
CAD coronary artery disease, GSH reduced glutathione, GSSG oxidised glutathione, OxLDL oxidised low density lipoprotein cholesterol, PMA phorbol-12-myristate-
13-acetate. Data are given as median [interquartile range]. P-values are derive from Mann–Whitney U-tests.
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minants of PWV using both a model where all variables
were forced in and then a stepwise model (Pin < 0.05 and
Pout > 0.10). For interaction analysis between eGFR and
CAD status we centered eGFR around the mean ofTable 3 Circulating biomarkers
CAD
n = 109
eGFR ≥60 mL/min eGFR <60 mL/min
n = 71 n = 38
E-selectin (ng/mL) 10.5 [10.4] 17.6 [12.6]
P-selectin (ng/mL) 90.4 [39.0] 106.1 [57.9]
ICAM-1 (ng/mL) 27.6 [11.4] 34.5 [21.9]
VCAM-1 (μg/mL) 1.37 [1.26] 2.03 [1.36]
sRAGE (ng/mL) 3.8 [2.5] 4.8 [4.7]
ENRAGE (ng/mL) 73.2 [81.0] 65.3 [149.9]
IL-8 (pg/mL) 4.0 [3.7] 3.8 [4.1]
MCP-1 (pg/mL) 44.6 [31.8] 50.8 [48.1]
MIP-1β (pg/mL) 66.2 [50.4] 73.5 [56.5]
CRP (mg/L) 2.0 [2.2] 2.4 [2.9]
TNF-α (pg/mL) 0.73 [1.14] 0.96 [1.63]
PAI-1(ng/mL) 219.0 [198.6] 152.5 [265.8]
Adiponectin (μg/mL) 4.1 [3.9] 5.6 [6.9]
Osteopontin(ng/mL) 0.5 [1.0] 1.8 [4.0]
Leptin (ng/mL) 9.1 [8.0] 15.0 [27.3]
CAD coronary artery disease, eGFR estimated glomerular filtration rate, ICAM-1 inter
sRAGE soluble receptor of advanced glycation end-products, ENRAGE extracellular n
MCP-1 monocyte chemoattractant protein 1, MIP-1β macrophage inflammatory pro
PAI-1 plasminogen activator inhibitor-1. Data are given as median [interquartile ran
<60 mL/min groups.eGFR and calculated an interaction term by multiplying
centered eGFR with CAD status (coded as 1 = “no
CAD”, 2 = “CAD”); these terms were then used in linear
regression analysis. A P-value of 0.05 (two sided) was
considered significant.No CAD
n = 86
P-value eGFR ≥60 mL/min eGFR <60 mL/min P-value
n = 40 n = 46
<0.001 10.8 [6.6] 19.2 [14.2] <0.001
0.015 85.6 [45.9] 113.0 [45.9] 0.001
0.002 23.0 [12.6] 33.1 [15.6] <0.001
0.006 0.96 [0.75] 1.42 [0.95] 0.008
0.110 3.8 [3.0] 6.7 [5.9] <0.001
0.794 53.9 [56.9] 38.3 [32.2] 0.059
0.218 3.2 [3.0] 5.1 [4.4] 0.005
0.488 54.9 [40.2] 70.3 [53.7] 0.009
0.258 66.4 [48.2] 95.0 [91.1] 0.029
0.138 1.3 [1.9] 2.9 [4.8] <0.001
0.182 0.65 [0.62] 1.73 [1.29] <0.001
0.329 175.8 [221.0] 153.8 [101.8] 0.044
0.020 3.5 [4.6] 5.9 [9.3] 0.047
<0.001 0.0 [0.9] 9.4 [17.9] <0.001
0.011 6.4 [9.0] 16.3 [28.8] <0.001
cellular adhesion molecule-1, VCAM-1 vascular cell adhesion molecule-1,
ewly identified receptor for advanced glycation end-products binding protein,
tein-1 beta, CRP C-reactive protein, TNF-α, tumour necrosis factor alpha,
ge]. P-values refer to comparisons between the eGFR ≥60 mL/min and eGFR
Table 4 Correlations between biomarkers and PWV and eGFR
eGFR PWV
ρ P-value ρ P-value
E-selectin −0.441 <0.001 0.281 0.006
P-selectin −0.272 <0.001 0.125 0.228
ICAM-1 −0.541 <0.001 0.193 0.061
VCAM-1 −0.264 <0.001 0.417 <0.001
sRAGE −0.369 <0.001 0.052 0.615
ENRAGE 0.086 0.215 0.143 0.167
IL-8 −0.208 0.002 0.106 0.305
MCP-1 −0.203 0.003 0.069 0.505
MIP-1β −0.130 0.061 0.185 0.073
C-reactive protein −0.214 <0.001 0.272 <0.001
TNF-α −0.323 <0.001 0.218 0.034
PAI-1 0.157 0.023 0.072 0.489
Adiponectin −0.239 <0.001 .0245 0.017
Osteopontin −0.602 <0.001 0.377 <0.001
Calcium −0.312 0.001 −0.126 0.317
Phosphate 0.977 <0.001 0.261 0.037
Calcium × Phosphate −0.329 0.001 0.207 0.101
Leptin −0.384 <0.001 0.268 0.009
eGFR estimated glomerular filtration rate, PWV pulse wave velocity,
ICAM-1 intercellular adhesion molecule-1, VCAM-1 vascular cell adhesion
molecule-1, sRAGE soluble receptor of advanced glycation end-products,
ENRAGE extracellular newly identified receptor for advanced glycation
end-products binding protein, MCP-1 monocyte chemoattractant protein 1,
MIP-1β macrophage inflammatory protein-1 beta, TNF-α tumor necrosis factor
alpha, PAI-1 plasminogen activator inhibitor-1. Spearman correlation
coefficients (ρ) and associated P-values are given.
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Study cohort
Clinical and demographic characteristics of study partici-
pants are presented in Table 1. As expected, patients with
CAD and/or eGFR < 60 mL/min were older than control
subjects, and due to lipid-lowering therapy, total and LDL
cholesterol levels were lowest in patients with CAD. Blood
pressure was similar across the study groups.
Pulse wave velocity
PWV was greater in patients with eGFR < 60 mL/min
compared to those with eGFR ≥60 mL/min, both in pa-
tients without CAD (10.2 [9.1;11.2] vs 7.3 [6.9;7.7] m/s;
P < 0.001) and with CAD (10.1 [8.9;11.2] vs 8.1 [7.5;8.7]
m/s; P = 0.001). In those with an eGFR <60 mL/min,
there was no difference in PWV between patients with
and without CAD (P = 0.935). In contrast, PWV was
greater in the CAD group when only patients with nor-
mal renal function were selected (P = 0.029) (Figure 1A).
Assessing eGFR as a continuous variable, a close cor-
relation was found between PWV and eGFR (r = −0.476;
P < 0.001) in the whole study cohort (Figure 1B). Linear
regression analysis demonstrated that eGFR (β = −0.293;
P < 0.001) contributed to PWV independently of age
(β = 0.453; P < 0.001) and systolic blood pressure
(β = 0.153; P = 0.009); whereas presence or absence of
CAD (β = −0.015; P = 0.798), sex (β = 0.040; P = 0.523)
and body mass index (β = 0.064; P = 0.294) did not con-
tribute significantly. A model containing only age, sys-
tolic blood pressure and eGFR explained 42% of the
variability of PWV.
Linear regression analysis to study interaction between
CAD and eGFR confirmed the key role of eGFR as de-
terminant of PWV. Centered eGFR (β = − 0.603, P =
0.002), but not CAD status (β-0.081; P = 0.191) and the
interaction term (β = 0.137, P = 0.479) significantly con-
tributed to the model explaining PWV.
Oxidative stress
We explored if markers of oxidative stress differed between
patients with CAD and those without CAD. In line with
our previous observations [16,17] we found significantly in-
creased levels of oxidative stress markers in patients with
CAD compared with those without (Table 2). In contrast,
no significant differences were found in patients with CAD
when stratified into groups with normal or impaired renal
function (Table 2). Oxidative stress therefore does not seem
to explain the increased vascular stiffness associated with
impaired renal function in patients with CAD.
Phosphate and circulating biomarkers of inflammation
and cell adhesion
We then studied circulating biomarkers of inflammation
and cell adhesion in control subjects and in patients withCAD of which both were stratified into groups with nor-
mal or impaired renal function. As expected, a number of
markers were different between those with and without
impaired renal function in the control group (Table 3). In
a next step we analysed correlations between these
markers and PWVand eGFR in the whole cohort (Table 4).
We found that levels of E-selectin, VCAM-1, adiponectin,
osteopontin and leptin were consistently different between
groups with and without impaired renal function and were
correlated with both eGFR and PWV. Scatterplots for
these markers illustrating potential correlations that could
provide a link between renal function and vascular stiff-
ness are shown in Figure 2.
When added to the multivariate model to study the as-
sociation of the markers with PWV independently of
eGFR, age, systolic blood pressure, sex, presence or ab-
sence of CAD and body mass index only E-selectin (β =
0.307, P < 0.001; also included: age [β = 0.617, P < 0.001]),
osteopontin (β = 0.336, P < 0.001; also included: age [β =
0.538, P < 0.001], body mass index [β = 0.188, P = 0.021])
and adiponectin (β = 0.203, P = 0.017; also included: age
[β = 0.502, P < 0.001], eGFR [β = − 0.186, P = 0.036] and
systolic blood pressure [β = 0.215, P = 0.014]) were part of
AB
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Figure 2 Correlations between renal function, vascular stiffness
and circulating biomarkers of inflammation and cell adhesion.
Panels A to G (left) show scatterplots of E-selectin, vascular cell
adhesion molecule-1 (VCAM-1), adiponectin, osteopontin, leptin,
C-reactive protein (CRP) and phosphate against estimated glomerular
filtration rate (eGFR). Panels H to N (right) show scatterplots of pulse
wave velocity (PWV) against these circulating markers. Data for
osteopontin, leptin and CRP have been log transformed for these plots.
Open symbols: no coronary artery disease; closed symbols: coronary
artery disease. Spearman correlation coefficients and associated
P-values are displayed in Table 4.
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to PWV remained statistically significant even after add-
itional adjustment for phosphate (osteopontin, β = 0.206,
P = 0.049; also included: age [β = 0.638, P < 0.001] and sys-
tolic blood pressure [β = 0.205; P = 0.046]) or calcium
(osteopontin, β = 0.287, P = 0.005; also included: age [β =
0.631, P < 0.001]). Phosphate, CRP, VCAM-1 and leptin
were no significant determinants of PWV when adjusted
for other factors.Discussion
In this study we demonstrate that arterial stiffness is
greater in individuals with impaired renal function com-
pared to those with eGFR ≥60 mL/min, even in the pres-
ence of advanced CAD. The greater vascular stiffness in
the group with impaired renal function was paralleled by
differences in markers of inflammation and cell adhesion
but not by markers of oxidative stress. We found a close
relationship between renal function and PWV, suggesting
that renal impairment has an incremental negative effect
on arterial stiffness in patients with established CAD. In-
deed, impaired renal function was found to be a far stron-
ger determinant of PWV than presence of CAD itself.Vascular stiffness
Increased vascular stiffness is an independent predictor of
cardiovascular outcome [2,20,21]. Impaired renal function
is associated with vascular stiffening, but the underlying
mechanisms are incompletely understood [1,10,11,22,23].
From a recent study by Ilyas et al. [8] it appears that there
is an additive contribution of impaired renal function to
vascular stiffness even in patients with moderately severe
CAD. In our present study we have gone one step further
and studied patients with severe triple vessel CAD who re-
quire surgical revascularisation, compared them with pa-
tients without CAD and assessed a wide range of markers
of oxidative stress, inflammation and cell adhesion.
We have previously reported reduced aortic compli-
ance in patients with ESRD [7]. In the present study we
not only found a linear relationship between renal excre-
tory function and vascular stiffness in mild-to-moderate
renal impairment, but also demonstrated that this
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factors including systolic blood pressure and age.
Circulating biomarkers and oxidative stress
Inflammatory processes play an important role in the
pathogenesis of vascular disease [9], and renal impair-
ment has been identified as a chronic low grade inflam-
matory state [11]. The present study demonstrates that
levels of E selectin and VCAM-1 are increased in
patients with CAD and renal impairment relative to pa-
tients with CAD alone. In multivariate analysis only E-
selectin was an independent predictor of PWV, and the
final model only contained age and E-selectin but not eGFR
or blood pressure. It therefore appears plausible, although
not directly proven in this cross-sectional study, that effects
of impaired renal function on vascular stiffness are at least
in part mediated by increased levels of E-selectin. We have
previously demonstrated a role of E-selectin in the early
stages of pre-eclampsia, a condition that is also associated
with renal damage and endothelial dysfunction [24]. Other
studies [25,26] reported that adhesion molecules are inde-
pendent predictors of cardiovascular events in patients with
ESRD, although not all studies confirm these data [27].
Adhesion of inflammatory cells to the endothelium is an
early step in the development of vascular disease and fur-
ther induces local vascular inflammation [28].
We have also found independent associations of osteo-
pontin and adiponectin with vascular stiffness. Osteopontin
is an extracellular matrix protein that contributes to the
development of atherosclerosis as it acts as a pro-
inflammatory cytokine to induce macrophage adhesion and
migration, it promotes vascular smooth muscle cell prolif-
eration and may mediate vascular calcification [29].
Osteopontin mRNA is expressed in aortic atherosclerotic
plaques in patients with CAD, but not in the arteries of
healthy controls, and expression is proportional to severity
of disease [30]. In a prospective study of patients with
established CAD, osteopontin was an independent pre-
dictor of fatal and nonfatal cardiovascular events even after
adjustment for traditional risk factors [31]. Lorenzen et al.
[29] demonstrated that in patents with CKD, osteopontin
levels increase linearly with progressive decline in GFR.
Our study suggests that osteopontin levels are further in-
creased in patients with CAD and concomitant renal im-
pairment, and thus may contribute to the development of
vascular disease in this group. It is important to note that
the association between osteopontin and vascular stiffness
in our study was independent of calcium or phosphate
levels. The findings on adiponectin are more difficult to in-
terpret. Adiponectin is an adipose tissue-derived protein
that is generally thought to have vasoprotective properties.
Lower levels of adiponectin have been found in a number
of cardiovascular conditions including diabetes [32] and
hypertension [33]. On the other hand, renal failure isassociated with reduced clearance of adiponectin, and a re-
cently proposed interaction between cystatin C and
adiponectin could explain the paradoxical finding of high
adiponectin levels in renal failure and the absence of a
vasoprotective effect under these conditions [34].
Oxidative stress has been proposed as a unifying con-
cept to explain the pathophysiology of cardiovascular
disease in uraemic patients [11]. We have previously
shown that vascular superoxide production is a signifi-
cant determinant of vascular stiffness in patients without
renal disease [16]. Levels of reactive oxygen species are
increased in patients with CAD [12,17], but in our
present study there was no further rise in oxidative
stress to explain the increased vascular stiffness in those
with concomitant renal impairment. However, increased
expression of adhesion molecules may lead to increased
numbers of inflammatory cells in the vessel wall and
thereby promote functional and structural changes.
Limitations
A limitation of our study is that renal impairment was
assessed by estimating GFR from serum creatinine using
the MDRD equation. eGFR is a measure of renal function
which also integrates other important determinants of
vascular stiffness, namely age and sex. Without exact meas-
urement of GFR (e.g. by inulin clearance) we cannot pre-
cisely separate the effect of renal impairment from that of
age on vascular stiffness. However, this issue has been
raised in other studies as well and it is not necessarily a
limitation [35]. In fact, eGFR captures risk related to a
number of characteristics and is an excellent surrogate
marker in clinical practice [35,36]. We acknowledge, how-
ever, that assessment of renal function at a single time point
does not take variability of renal function in response to
diet, fluid intake and medication into account.
Another limitation of this study is the cross-sectional
design, which precludes inferences about the contribu-
tion of renal impairment on vascular stiffness and the ef-
fect on future cardiovascular risk, especially as vascular
stiffening itself is a process progressing over a long
period of time, where improvements of vascular stiffness
are associated with improved outcome in patients with
CAD [37]; rather we must limit ourselves to showing
differences between patient groups. However, vascular
stiffness is an established independent predictor of car-
diovascular outcome in the general population [38,39],
in patients with CAD [21] and in individuals on dialysis
[2,40]. Recently, Ilyas et al. [8] suggested that assessment
of arterial stiffness in patients with established CAD and
mild renal impairment has some prospective value, as
lower GFR and higher PWV predicted a shorter time to
cardiovascular hospitalization and all cause mortality.
We also acknowledge that we did not control for drug
therapy in this study. Therefore a number of potentially
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fected by statin therapy which is especially prevalent in
patients with CAD, may not be adequately represented
in our analyses.
Finally, residual confounding is a potential limitation
of any study using multivariate analysis. We apreciate
that other factors than renal function may have add-
itional effects on vascular stuffness.
Conclusions
In summary we have demonstrated that even in patients
with advanced atherosclerotic disease, concomitant renal
impairment is associated with a further increase in vas-
cular stiffness. Our study highlights the pre-eminent role
of renal function as a cardiovascular risk factor and jus-
tifies efforts to preserve renal function, especially in pa-
tients with established cardiovascular diseases. Due to
the cross-sectional design, we were unable to demon-
strate a direct causal relationship between the changes
seen in circulating biomarkers and vascular stiffness.
However, the pattern seen suggests that renal impair-
ment may aggravate vascular disease by effects on cell
adhesion and inflammation.
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